美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

bioAffinity Technologies Equity Warrants Exp 23 June 2027 Warrant

0.2279

0.0000

成交量：- -

成交额：564.72

市值：648.80万

市盈率：-0.01

高：0.2279

开：0.2279

低：0.2279

收：0.2279

52周最高：0.8121

52周最低：0.0525

股本：2,846.86万

流通股本：2,846.86万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-20.7379

净资产收益率：-301.83%

总资产收益率：-75.63%

市净率：0.89

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

bioAffinity Technologies启动其非侵入性Cypath®肺癌诊断技术的大规模纵向临床研究

bioAffinity Technologies携手布鲁克陆军医疗中心启动验证研究，拓展Cypath® Lung无创肺癌早筛检测的样本采集选项

bioAffinity Technologies宣布获得美国专利申请的允许通知，涉及其肺癌诊断算法和检测方法

bioAffinity Technologies, Inc.宣布完成约180万美元普通股注册直接融资，定价符合纳斯达克市场规则

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BIAFW"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIAFW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIAFW\",,,,,undefined,":{"symbol":"BIAFW","market":"US","secType":"STK","nameCN":"bioAffinity Technologies Equity Warrants Exp 23 June 2027 Warrant","latestPrice":0.2279,"timestamp":1777474128802,"preClose":0.2279,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":28468614,"shares":28468614,"eps":-20.7379,"marketStatus":"交易中","change":0,"latestTime":"04-29 10:48:48 EDT","open":0.2279,"high":0.2279,"low":0.2279,"amount":564.7229172,"amplitude":0,"askPrice":0.4289,"askSize":50,"bidPrice":0.2264,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-20.7379,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1777492800000},"marketStatusCode":2,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":0.2279,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIAFW\",,,,,undefined,":{"symbol":"BIAFW","floatShares":28468614,"roa":"-75.63%","roe":"-301.83%","lyrEps":0,"shares":28468614,"dividePrice":0,"high":0.2279,"amplitude":0,"preClose":0.2279,"low":0.2279,"week52Low":0.0525,"pbRate":"0.89","psRate":"1.05","week52High":0.8121,"institutionHeld":0,"latestPrice":0.2279,"committee":0.333333,"eps":-20.7379,"divideRate":0,"volume":0,"delay":0,"ttmEps":-20.7379,"open":0.2279,"prevYearClose":0.35,"prevWeekClose":0.31,"prevMonthClose":0.4525,"prevQuarterClose":0.4525,"fiveDayClose":0.3267,"twentyDayClose":0.4525,"sixtyDayClose":0.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIAFW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"BIAFW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘前","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIAFW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIAFW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIAFW\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1158495268","title":"bioAffinity Technologies启动其非侵入性Cypath®肺癌诊断技术的大规模纵向临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1158495268","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158495268?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 19:49","pubTimestamp":1773143344,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies公司宣布，已启动一项针对其非侵入性Cypath®肺癌诊断技术的大规模纵向临床研究。该研究旨在通过长期跟踪和数据收集，进一步验证该诊断方法的有效性与可靠性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAFW","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186193545","title":"bioAffinity Technologies携手布鲁克陆军医疗中心启动验证研究，拓展Cypath® Lung无创肺癌早筛检测的样本采集选项","url":"https://stock-news.laohu8.com/highlight/detail?id=1186193545","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186193545?lang=zh_cn&edition=fundamental","pubTime":"2026-02-25 21:32","pubTimestamp":1772026320,"startTime":"0","endTime":"0","summary":"生物亲和技术公司（bioAffinity Technologies）宣布，将与布鲁克陆军医疗中心（Brooke Army Medical Center）合作开展一项验证研究，旨在扩大其Cypath® Lung无创早期肺癌检测技术的样本采集方式。此项研究将评估不同样本采集方案的有效性，以提升该检测技术的可及性和应用便利性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAFW","BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142229976","title":"bioAffinity Technologies宣布获得美国专利申请的允许通知，涉及其肺癌诊断算法和检测方法","url":"https://stock-news.laohu8.com/highlight/detail?id=1142229976","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142229976?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 20:01","pubTimestamp":1760616074,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies宣布获得美国专利申请的允许通知，涉及其肺癌诊断算法和检测方法","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF","BIAFW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129857267","title":"bioAffinity Technologies, Inc.宣布完成约180万美元普通股注册直接融资，定价符合纳斯达克市场规则","url":"https://stock-news.laohu8.com/highlight/detail?id=1129857267","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129857267?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 03:47","pubTimestamp":1759952838,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies, Inc.日前宣布完成约180万美元的注册直接融资，本次融资通过发行普通股实现，股票定价按照纳斯达克市场规则执行。\n此次融资采用按市价定价的方式进行，严格遵循纳斯达克交易所的相关规定和要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAFW","BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BIAFW\",params:#limit:6,delay:false,,,undefined,":[]}}